An update on autoimmune retinopathy

• Main Authors: Parthopratim Dutta Majumder, Alessandro Marchese, Francesco Pichi, Itika Garg, Aniruddha Agarwal
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2020-01-01
• Series: Indian Journal of Ophthalmology
• Subjects: autoimmune retinopathy; cancer-associated retinopathy; enolase; melanoma-associated retinopathy; recoverin
• Online Access: http://www.ijo.in/article.asp?issn=0301-4738;year=2020;volume=68;issue=9;spage=1829;epage=1837;aulast=Dutta

Autoimmune retinopathy (AIR) refers to a group of rare autoimmune retinal degenerative diseases presumably caused by cross-reactivity of serum autoantibodies against retinal antigens. The pathogenesis of AIR remains largely presumptive and there are a significant number of antiretinal antibodies that have been detected in association with AIR. The diagnosis of AIR is largely based on the demonstration of antiretinal antibodies in the serum along with suggestive clinical features and ancillary investigations. A high index of suspicion along with early diagnosis and treatment may play a critical role to lower the risk of irreversible immunological damage to the retinal cells in these patients. A multi-disciplinary approach for complete management and evaluation is helpful in such conditions. Various therapeutic options have been described for the treatment of AIR, though there is no consensus on standard treatment protocol.